Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.2
3.0
Journals
Animals
Special Issues
Development of Novel Vaccines in Animals
share announcement

Development of Novel Vaccines in Animals

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Veterinary Clinical Studies".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3201

Special Issue Editor

Dr. Engin Berber

E-Mail Website
Guest Editor
Biomedical and Diagnostic Sciences, The University of Tennessee, Knoxville, TN, USA
Interests: vaccine; vaccine development; virology; immunology; humoral response; cellular immunity; HSV; Crimean-Congo haemorrhagic fever; T cell; immunometabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Animal vaccines in veterinary medicine are generally considered to be one of the most cost-effective and sustainable methods. The development of veterinary vaccines has been ongoing for centuries, since the invention of the first animal vaccines by Louis Pasteur, who developed many vaccines including chicken cholera, anthrax and rabies vaccines for animal use. The modern veterinary vaccine development era has seen unprecedented expansion and led to the development of many other vaccines to control animal diseases. Controlling infectious veterinary diseases is also found to be important for zoonotic infections in terms of public health.

The development of novel vaccine technologies has enabled us to reduce the vaccine production cost and time and improve vaccine safety and efficacy. These vaccine platforms including DNA, viral vector-based delivery systems, virus-like particles, protein or peptide vaccines and mRNA vaccines have been used in veterinary research and clinic fields for many years to demonstrate the therapeutic efficacies of novel vaccines. A mounting number of novel veterinary vaccine studies have been published and many are still under development.

In this Veterinary Clinical Studies section of the Animals journal, we aim to collect original research studies addressing veterinary vaccine development for the Special Issue: Development of Novel Vaccines in Animals. Researchers working in academia and industry are strongly encouraged and welcome to submit their reviews and opinions on this novel veterinary vaccine development topic. As a Guest Editor of this Special Issue, I invite scientists to submit their work, including, but not limited to, virology, microbiology, immunology and parasitology disciplines.

Dr. Engin Berber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • veterinary vaccines
  • vaccine development
  • novel vaccines
  • vaccine strategies
  • animal health
  • infectious diseases
  • zoonosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 3439 KiB  
Communication
Evaluation of Two Recombinant Protein-Based Vaccine Regimens against Campylobacter jejuni: Impact on Protection, Humoral Immune Responses and Gut Microbiota in Broilers
by Noémie Gloanec, Muriel Guyard-Nicodème, Raphaël Brunetti, Ségolène Quesne, Alassane Keita, Marianne Chemaly and Daniel Dory
Animals 2023, 13(24), 3779; https://doi.org/10.3390/ani13243779 - 07 Dec 2023
Cited by 1 | Viewed by 1019
Abstract
Campylobacter infections in humans are traced mainly to poultry products. While vaccinating poultry against Campylobacter could reduce the incidence of human infections, no vaccine is yet available on the market. In our previous study using a plasmid DNA prime/recombinant protein boost vaccine regimen, [...] Read more.
Campylobacter infections in humans are traced mainly to poultry products. While vaccinating poultry against Campylobacter could reduce the incidence of human infections, no vaccine is yet available on the market. In our previous study using a plasmid DNA prime/recombinant protein boost vaccine regimen, vaccine candidate YP437 induced partial protective immune responses against Campylobacter in broilers. In order to optimise vaccine efficacy, the vaccination protocol was modified using a protein prime/protein boost regimen with a different number of boosters. Broilers were given two or four intramuscular protein vaccinations (with the YP437 vaccine antigen) before an oral challenge by C. jejuni during a 42-day trial. The caecal Campylobacter load, specific systemic and mucosal antibody levels and caecal microbiota in the vaccinated groups were compared with their respective placebo groups and a challenge group (Campylobacter infection only). Specific humoral immune responses were induced, but no reduction in Campylobacter caecal load was observed in any of the groups (p > 0.05). Microbiota beta diversity analysis revealed that the bacterial composition of the groups was significantly different (p ≤ 0.001), but that vaccination did not alter the relative abundance of the main bacterial taxa residing in the caeca. The candidate vaccine was ineffective in inducing a humoral immune response and therefore did not provide protection against Campylobacter spp. infection in broilers. More studies are required to find new candidates. Full article
(This article belongs to the Special Issue Development of Novel Vaccines in Animals)
►▼ Show Figures

Figure 1

12 pages, 266 KiB  
Article
Increased Effect of Foot-and-Mouth Disease Virus Vaccine Structural Protein Antibody Positivity Rates in Piglets Orally Treated with Amino–Zinc Complex
by Byoung-Ryol Lee, Hu-Jang Lee, Nam-Hoon Kim, Yong-Sik Kim and Kwang Il Park
Animals 2023, 13(12), 2027; https://doi.org/10.3390/ani13122027 - 18 Jun 2023
Viewed by 1511
Abstract
Foot-and-mouth disease (FMD) is a highly contagious animal disease that occurs in cloven-hoofed animals including pigs. To prevent FMD, vaccines and adjuvants are routinely used to induce an immune response; however, it requires an extended period of time to produce sufficient antibodies to [...] Read more.
Foot-and-mouth disease (FMD) is a highly contagious animal disease that occurs in cloven-hoofed animals including pigs. To prevent FMD, vaccines and adjuvants are routinely used to induce an immune response; however, it requires an extended period of time to produce sufficient antibodies to prevent viral infection. In this study, we evaluated the increased effectiveness of the FMD vaccine structural protein (SP) antibody by administrating the Amino–Zn adjuvant to 100 pigs from 3 test pig farms in their feed. The FMD vaccine antibody titer and immunological index were analyzed using an enzyme-linked immunosorbent assay (ELISA) kit, and the hematological and blood biochemical parameters were analyzed using an automatic blood analyzer. The titer of the FMD vaccine SP antibodies in the 0.2% Amino–Zn-administered group was significantly increased compared to that of the positive control group only injected with FMD vaccine at 4 weeks after the first vaccination and at 4, 8, and 16 weeks after the second vaccination (p < 0.05). The FMD vaccine SP antibody positive rate was 100% until shipment. The IFN-γ and IgA levels were significantly increased by Amino–Zn administration 4 weeks after the first vaccination and 4 weeks after the second vaccination (p < 0.05). On the other hand, serum AST, and CPK (p < 0.001) were significantly decreased by Amino–Zn administration. These results show that the administration of Amino–Zn is effective in enhancing the antibody titer and immunogenicity of the FMD vaccine and can be used as an oral adjuvant (OrAd) to prevent viral diseases, such as FMD. Full article
(This article belongs to the Special Issue Development of Novel Vaccines in Animals)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop